Skip to content
Menu

BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.

BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.

Read at benzinga.com

← All stock news